Cargando…
Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption
CONTEXT: The effect of sotagliflozin (a dual sodium–glucose cotransporter [SGLT] 2 and SGLT1 inhibitor) on intestinal glucose absorption has not been investigated in humans. OBJECTIVE: To measure rate of appearance of oral glucose (R(a)O) using a dual glucose tracer method following standardized mix...
Autores principales: | Powell, David R, Zambrowicz, Brian, Morrow, Linda, Beysen, Carine, Hompesch, Marcus, Turner, Scott, Hellerstein, Marc, Banks, Phillip, Strumph, Paul, Lapuerta, Pablo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7067537/ https://www.ncbi.nlm.nih.gov/pubmed/31837264 http://dx.doi.org/10.1210/clinem/dgz258 |
Ejemplares similares
-
OR22-5 Sotagliflozin Decreases Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption
por: Powell, David, et al.
Publicado: (2019) -
Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes
por: Sands, Arthur T., et al.
Publicado: (2015) -
Relationships of Glucose, GLP-1, and Insulin Secretion With Gastric Emptying After a 75-g Glucose Load in Type 2 Diabetes
por: Jalleh, Ryan J, et al.
Publicado: (2022) -
Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes
por: Powell, David R, et al.
Publicado: (2015) -
Dichotomy in the Impact of Elevated Maternal Glucose Levels on Neonatal Epigenome
por: Lim, Ives Yubin, et al.
Publicado: (2021)